

Note

Synthesis of 2-*O*-(2-iodoethyl)-D-glucose, a stable iodinated analogue of 2-deoxy-2-fluoro-D-glucoseGilles Bignan, Christophe Morin ^{*}, Michel Vidal*Laboratoire de Chimie Organique, LEDSS Bâtiment 52, Université de Grenoble, BP-53 X, F-38041 Grenoble, France*

Received 23 November 1994; accepted 22 December 1994

Keywords: Iodinated glucose; β -Iodoethoxyl; Radioiodination; FDG analogue; SPECT

2-Deoxy-2-[^{18}F]fluoro-D-glucose, **1** (FDG) is used in nuclear medicine for brain and ischemic myocardiac tissue imaging [1–3]. The required fluorine isotope, a positron emitter, has however a short half-life ($t_{1/2}$ 110 min) which severely limits its usefulness, and production of FDG and its medical use require the proximity of the ^{18}F producing cyclotron. Therefore, efforts are being made in order to replace the fluorine atom with iodinated units so as to be able to use the γ -emitter ^{123}I ($t_{1/2}$ 13.2 h) for the widespread Single Photon Emmitting Computer Tomography (SPECT) imaging [4].


Unfortunately, direct replacement of the fluorine atom by iodine as in 2-deoxy-2-iodo-D-glucose [5,6] **2** leads to an unstable derivative. Hence, several analogues in which iodine is linked to a vinyl [7] or an aromatic group [8–13] have been prepared. Having recently disclosed that the β -iodoethoxy moiety behaves as a stable and less bulky iodinated unit [14], we now report the preparation of the corresponding β -iodoethoxy analogue of FDG, namely **3**.

For the synthesis of **3**, a D-glucose acetate derivative having a free hydroxyl group at C-2 was selected as the starting material. However, as literature methods for the introduction of the β -iodoethoxyl group [14–21] were not compatible with the presence of acetates, another procedure for the introduction of the β -iodoethoxyl group was needed. The silver salt of **4**, readily available from D-glucose [22], was reacted with allyl bromide to afford **5** [23]. Surprisingly however, **5** turned out to be inert to prolonged ozonolysis which thus required modification of the protection at the anomeric position. Conversion [23] of **5** to **6** gave a $\sim 1:1$ mixture of α/β anomers which then could be reacted with ozone. The intermediate aldehyde was immediately reduced to **7**, the ratio

^{*} Corresponding author.

of anomers becoming $\sim 1:3$, a fact which is most likely due to a difference in the reactivity of each anomer. Conversion of the anomeric mixture of alcohols **7** to iodides **8** was then accomplished conventionally using freshly prepared [24] triiodoimidazole. While removal of the acetates by using a stoichiometric amount of sodium methoxide unexpectedly led to the known [25–27] bicyclic **9**, the desired conversion to **3** could be achieved in 80% yield with a catalytic amount of sodium methoxide (-30°C , 13 days).

Compound **3** is a simple and stable iodinated analogue of FDG and, since its radiolabelling can be performed efficiently by isotopic exchange, it is currently being evaluated as a metabolic tracer of D-glucose.



1. Experimental

General methods.—Toluene and CH₂Cl₂ were dried over 4 Å molecular sieves and MeOH was distilled over magnesium. After work-up, the volatiles were evaporated under reduced pressure without heating. Standard abbreviations are used for NMR description of spectra which were recorded on Bruker and Varian apparatus using built-in software, at the field and in the solvent indicated for each compound. The residual absorption of the NMR solvent was taken as the internal reference, except for ¹³C NMR spectra in water. Standard abbreviations are used with m for multiplet and M for unresolved multiplet. IR spectra were recorded on a Perkin–Elmer 397 spectrophotometer and a Perkin–Elmer 241 polarimeter was used for the determination of optical rotations.

1,3,4,6-tetra-O-acetyl-2-O-(2-hydroxyethyl)-α- and -β-D-glucopyranose (7).—A stirred solution of **6** [23] (280 mg, 0.72 mmol) in dry CH₂Cl₂ (40 mL) and dry MeOH (12 mL) at -78°C was ozonized till persistence of a blue color (1 h). Ozone was removed by a slow stream of oxygen followed by argon. Excess dimethyl sulfide was then slowly added at -78°C to the now colorless solution, and the cooling bath was removed. Evaporation of volatiles left the crude aldehyde [¹H NMR (300 MHz, CDCl₃): 9.6 (m, 1 H, –CHO), 6.4 (d, 1 H, *J*_{1,2} 3.4 Hz, H-1α), 5.6 (d, 1 H, *J*_{1,2} 3.8 Hz, H-1β), 5.4–4.95 (M, 4 H), 4.6–4.4 (M, 1 H), 4.3–3.2 (M, 11 H), 2.14–1.98 (4 s, 12 H, –COCH₃)]. To a solution of the freshly prepared preceding aldehyde in MeOH (20

mL) at 4° C, was added portionwise NaBH₄ (136 mg, 3.6 mmol). After stirring for 30 min, excess hydride was quenched with Me₂CO (3 mL). The solution was neutralized with dilute (0.5 M) aq HCl and MeOH evaporated under reduced pressure. The aqueous layer was then extracted with CH₂Cl₂ (4 × 20 mL) and the organic layers were dried. After evaporation of the volatiles, the mixture was purified by column chromatography on silica gel. Elution with 49:1 CH₂Cl₂–MeOH gave **7** as a ~ 1:3 α/β mixture of anomers (colorless oil, 161 mg, 57%). IR (film): 3500 cm⁻¹ (OH), 1750 cm⁻¹ (CO). The specified NMR assignments were confirmed with the help of TOCSY 1D experiments. ¹H NMR (500 MHz, CDCl₃); α anomer: 6.30 (d, 1 H, *J*_{1,2} 3.7 Hz, H-1), 5.28 (t, 1 H, *J* 9.7 Hz, H-3), 5.01 (t, 1 H, *J* 9.80 Hz, H-4), 4.25–4.00 (M, 3 H, H-5, H-6 and H-6'), 3.8–3.5 (M, 5 H, H-2, –OCH₂CH₂OH); β anomer: 5.55 (d, 1 H, *J*_{1,2} 8.2 Hz, H-1), 5.13 (t, 1 H, *J* 9.4 Hz, H-3), 4.98 (t, 1 H, *J* 9.8 Hz, H-4), 4.25–4.00 (M, 2 H, H-6 and H-6'), 3.80–3.70 (M, 1 H, H-5), 3.8–3.5 (M, 4 H, –OCH₂CH₂OH), 3.44 (t, 1 H, *J* 8.2 Hz, H-2). The 8 singlets (3 H each) at 2.12, 2.10, 2.02, 2.01 (2 ×), 2.00, 1.98 and 1.96 (–COCH₃) have not been specifically assigned to each anomer and the exchangeable proton is not seen in the spectrum. ¹³C NMR (50 MHz, CDCl₃): 170.5, 170.3, 170.2, 169.5, 169.3, 168.8 (CO), 93.3 (C-1 β anomer), 89.6 (C-1 α), 78.9, 77.4, 74.0, 72.4, 71.7, 69.7, 67.7 (C-2, C-3, C-4 and C-5), 74.4 and 73.6 (–OCH₂CH₂OH) 61.6, 61.4 (C-6), 20.9, 20.8, 20.6, 20.5 (–COCH₃). CIMS (NH₃–isobutane): 410 (100%, [M + NH₄]⁺), 350 (10%, [M – AcOH]⁺), 333 (5%, [392 – OAc]⁺), 273 (3%, [333 – AcOH]⁺), 255 (2%, [273 – H₂O]⁺), 213 (55%, [273 – AcOH]⁺), 153 (31%, [213 – C₂H₄O₂]⁺). HMRS: Calcd for C₁₆H₂₄O₁₁ + Na: 415.1216. Found: 415.1219.

1,3,4,6-Tetra-O-acetyl-2-O-(2-iodoethyl)-α- and -β-D-glucopyranose (8).—To a stirred solution of alcohol **7** (62 mg, 0.16 mmol) in dry toluene (10 mL) under Ar, were successively added Ph₃P (62 mg, 0.24 mmol) and freshly prepared triiodoimidazole [24] (53 mg, 0.12 mmol). The mixture was stirred under reflux for 3 h at which stage further Ph₃P (45 mg, 0.17 mmol) and triiodoimidazole (40 mg, 0.09 mmol) were added. After stirring at reflux temperature for 14 h, the mixture was cooled and hydrolyzed with freshly prepared saturated aq NaHSO₄ (10 mL). After 5 min stirring, iodine was added till a brown color persisted in the organic layer. The excess of iodine was then removed by addition of saturated aq NaS₂O₃ (30 mL). The organic layer was separated, diluted with toluene and Me₂CO (3 mL), washed with water (3 × 20 mL), and dried. The solvent was evaporated and the crude mixture was purified by column chromatography on silica gel. Elution with 99.5:0.5 CH₂Cl₂–MeOH gave **8** as an unseparable mixture of anomers (colorless oil, 63 mg, 79%); IR (film): 1750 cm⁻¹ (CO). The specified NMR assignments were confirmed by TOCSY 1D and COSY DQF experiments. ¹H NMR (500 MHz, CDCl₃); α anomer: 6.38 (d, 1 H, *J*_{1,2} 3.6 Hz, H-1), 5.38 (t, 1 H, *J* 9.7 Hz, H-3), 5.04 (t, 1 H, *J* 9.8 Hz, H-4), 4.32–4.27 (m, 1 H, H-6 or H-6'), 4.10–4.05 (M, 2 H, H-5 and H-6 or H-6'), 3.94–3.60 (M, 2 H, –OCH₂CH₂I), 3.65 (dd, 1 H, *J* 9.9 Hz, H-2), 3.18–3.14 (M, 2 H, –OCH₂CH₂I), 2.19, 2.10, 2.08, 2.04 (s, 12 H, –COCH₃); β anomer: 5.61 (d, 1 H, *J*_{1,2} 8.1 Hz, H-1), 5.20 (t, 1 H, *J* 9.4 Hz, H-3), 5.02 (t, 1 H, *J* 9.7 Hz, H-4), 4.32–4.27 (m, 1 H, H-6 or H-6'), 4.10–4.05 (m, 1 H, H-6 or H-6'), 3.90–3.67 (M, 3 H, H-5 and –OCH₂CH₂I), 3.51 (dd, 1 H, *J* 8.5, H-2), 3.18–3.14 (M, 2 H, –OCH₂CH₂I), 2.18, 2.09, 2.07, 2.03 (s, 12 H, –COCH₃). ¹³C NMR (50 MHz, CDCl₃): 170.5, 170.1, 169.6, 169.0, 168.6 (CO), 93.9 (C-1 β), 89.2 (C-1 α), 78.5, 76.9, 73.8,

72.4, 71.2, 69.7, 68.0, 67.9, (C-2, C-3, C-4 and C-5), 73.2 and 71.9 ($-\text{OCH}_2\text{CH}_2\text{I}$), 61.5 (C-6), 21.1, 21.0, 20.7, 20.6 ($-\text{COCH}_3$), 2.1 ($-\text{OCH}_2\text{CH}_2\text{I}$). CIMS (NH_3 -isobutane): 520 (1%, $[\text{M} + \text{NH}_4]^+$), 443 (18%, $[502 - \text{OCOCH}_3]^+$), 442 (6%, $[502 - \text{AcOH}]^+$), 383 (1%, $[443 - \text{AcOH}]^+$), 323 (82%, $[383 - \text{AcOH}]^+$), 197 (32%, $[383 - \text{C}_8\text{H}_{10}\text{O}_5]^+$), 186 (6%, $[383 - \text{C}_4\text{H}_7\text{IO}]^+$), 168 (13%, $[323 - \text{CH}_2\text{CH}_2\text{I}]^+$), 155 (100%, $[\text{CH}_2\text{CH}_2\text{I}]^+$), 127 (13%, $[155 - \text{CH}_2 = \text{CH}_2, \text{I}]^+$), 108 (17%, $[168 - \text{AcOH}]^+$). HMRS: Calcd for $\text{C}_{16}\text{H}_{23}\text{IO}_{10}^+\text{Na}$: 525.0233. Found: 525.0247.

2-O-(2-Iodoethyl)-D-glucose (**3**).—To a stirred solution at -30°C of **8** (44 mg, 0.088 mmol) in dry MeOH (3 mL) was added NaOMe (10.8 μL of a 1 M solution in dry MeOH). The mixture was stirred for 14 days at -30°C , diluted with water (10 mL) and MeOH was evaporated under reduced pressure. The pH was brought to 7.0 with dilute H_2SO_4 (0.012 M); after extraction with CH_2Cl_2 (3×10 mL), the aq layer was evaporated without heating and the crude product was purified by column chromatography on silica gel. Elution with 45:5 EtOAc-isopropanol gave **3** as a white solid (23.4 mg, 80%); mp $139\text{--}143^\circ\text{C}$; $[\alpha]_D^{20} + 22.1^\circ$ (5 min) $\rightarrow +21.2^\circ$ (3 h) (c 1.25, MeOH). The specified NMR assignments were secured with the help of various TOCSY 1D and GHMQC experiments. ^1H NMR (500 MHz, D_2O); β anomer: 4.7 (d, 1 H, $J_{1,2}$ 7.9 Hz, H-1), 3.87 (A part of an ABM system, 1 H, J_{ab} 12.3 Hz, H-6 or H-6'), 3.69 (B part of an ABM system, 1 H, J_{ab} 12.3 Hz, H-6 or H-6'), 3.53 (t_{app} , 1 H, J 9.0 Hz, H-3), 3.45–3.37 (M, 2 H, H-5 and H-4), 3.34 (M, 2 H, $-\text{OCH}_2\text{CH}_2\text{I}$), 3.12 (dd, 1 H, J 9.3 Hz and J 7.9 Hz, H-2); α anomer: 5.4 (d, 1 H, $J_{1,2}$ 3.6 Hz, H-1), 3.82–3.60 (M, 4 H, H-3, H-5, H-6 and H-6'), 3.40–3.37 (M, 2 H, H-2 and H-4), 3.34 (M, 2 H, $-\text{OCH}_2\text{CH}_2\text{I}$). The signals at 4.12–4.0 (M) and 3.94–3.92 (t) for $-\text{OCH}_2\text{CH}_2\text{I}$ have not been specifically assigned to each anomer. ^{13}C NMR (125 MHz, D_2O); β anomer: 95.7 (C-1), 82.6 (C-2), 75.8 (C-5), 75.2 (C-3), 73.1 or 71.4 ($\text{OCH}_2\text{CH}_2\text{I}$), 69.6 or 69.5 (C-4), 60.7 (C-6), 3.3 ($-\text{OCH}_2\text{CH}_2\text{I}$); α anomer: 90.2 (C-1), 79.55 (C-2), 73.1 or 71.4 ($\text{OCH}_2\text{CH}_2\text{I}$), 72.0 and 71.2 (C-3 and C-5), 69.6 or 69.5 (C-4), 3.3 ($\text{OCH}_2\text{CH}_2\text{I}$). CIMS (NH_3 -isobutane): 352 (0.5%, $[\text{M} + \text{NH}_4]^+$), 334 (2%, $[\text{M}]^+$), 317 (3%, $[334 - \text{OH}]^+$), 299 (6%, $[334 - 2\text{H}_2\text{O}]^+$), 281 (1%, $[334 - 3\text{H}_2\text{O}]^+$), 239 (3%, $[299 - \text{HOCH}_2 - \text{CHO}]^+$), 155 (100%, $[-\text{CH}_2\text{CH}_2\text{I}]^+$), 154 (61%, $[281 - \text{I}]^+$), 146 (8%, $[317 - \text{OCH}_2\text{CH}_2\text{I}]^+$), 144 (10%, $[299 - \text{CH}_2\text{CH}_2\text{I}]^+$), 127 (5%, $[\text{I}]^+$), 126 (3%, $[144 - \text{H}_2\text{O}]^+$).

Acknowledgements

M.-C. Brochier is thanked for her help in correlative NMR experiments and J. Ulrich (Institut de Biologie Structurale, Grenoble) for HRMS data. J.-P. Mathieu (Laboratoire de Biophysique, C.H.R.U., Grenoble) is thanked for making preliminary labeling experiments available to us. G.B. is grateful to the "Ministère de la Recherche et de la Technologie" for a MRT fellowship.

References

- [1] B.M. Gallagher, A. Ansari, H. Atkins, V. Casella, D.R. Christman, J.S. Fowler, T. Ido, R.R. MacGregor, P. Som, C.N. Wan, A.P. Wolf, D.E. Kuhl, and M. Reivich, *J. Nucl. Med.*, 18 (1977) 990–996.

- [2] M.E. Phelps, S.C. Huang, E.J. Hoffman, C. Selin, L. Sokoloff, and D.E. Kuhl, *Ann. Neurol.*, 6 (1979) 371–388.
- [3] M.E. Phelps, M.E. Hoffmann, C.Selin, S-C. Huang, G.Robinson, N. MacDonald, H.Schelbert, and D.E. Kuhl, *J. Nucl. Med.*, 19 (1978) 1311–1319.
- [4] A.Syrota and P. Jehenson, *Eur. J. Nucl. Med.*, 18 (1991) 897–923.
- [5] J.S. Fowler, R.E. Lade, R.R. MacGregor, C. Shiue, C.-N. Wan, and A.P. Wolf, *J. Labelled Compd. Radiopharm.*, 16 (1979) 7–9.
- [6] G. Kloster, P. Laufer, W. Wutz, and G. Stöcklin, *Eur. J. Nucl. Med.*, 8 (1983) 237–241.
- [7] M.M. Goodman, A.P. Callahan, and F.F. Knapp, Jr, *J. Labelled Compd. Radiopharm.*, 23 (1987) 1269–1270.
- [8] H. Saji, Y. Magata, Y. Arano, K. Horiuchi, K. Torizuka, and A. Yokoyama, *J. Nucl. Med.*, 28 (1987) 571.
- [9] Y. Magata, H. Saji, Y. Arano, K. Horiuchi, K. Torizuka, and A. Yokoyama, *Nucl. Med. Biol.*, 14 (1987) 7–13.
- [10] T. Lutz, H. Dougan, T. Rihela, M. Hudon, P. Cohen, W.R.E. Jamieson, and D.M. Lyster, *J. Labelled Compd. Radiopharm.*, 29 (1991) 535–545.
- [11] Y. Magata, H. Saji, Y. Ohmomo, C. Tanaka, J. Kanishi, and A. Yokoyama, *J. Labelled Compd. Radiopharm.*, 30 (1991) 300–301.
- [12] Y. Magata, H. Saji, Y. Ohmomo, C. Tanaka, J. Kanishi, and A. Yokoyama, *J. Labelled Compd. Radiopharm.*, 31 (1992) 317–328.
- [13] T. Lutz, H. Dougan, T. Rihela, C.V. Vo, and D.M. Lyster, *J. Labelled Compd. Radiopharm.*, 33 (1993) 327–344.
- [14] S.Hamant, J.-P. Mathieu, C.Morin, I.Trimcev, and M.Vidal, *Bioorg Med. Chem. Lett.* 4 (1994) 1687–1690.
- [15] F. Baumstark, *Ber. Dtsch. Chem. Ges.*, 7 (1874) 1172–1175.
- [16] C.W. Tasker and C.B. Purves, *J. Am. Chem. Soc.*, 71 (1949) 1017–1023.
- [17] C. Walling and R.T. Clark, *J. Org. Chem.*, 39 (1974) 1962.
- [18] R.C. Cambie, R.C. Haywar, J.L. Roberts, and P.S. Rutledge, *J. Chem. Soc., Perkin Trans. 1*, (1974) 1858–1864.
- [19] C. Georgoulis and J.M. Valery, *Synthesis*, (1978) 402–403.
- [20] G. Bignan, J.-P. Mathieu, L. Mauclair, C. Morin, and M. Vidal, *J. Labelled Compd. Radiopharm.*, 32 (1993) 584–585.
- [21] G. Bignan, C. Morin, and M. Vidal, *Carbohydr. Res.*, 248 (1993) 371–375.
- [22] J.E. Hodge and C.E. Rist, *J. Am. Chem. Soc.*, 74 (1952) 1498–1500.
- [23] M.K. Gurjar and S.M. Pawar, *Carbohydr. Res.*, 159 (1987) 325–327.
- [24] P.J. Garegg and B. Samuelsson, *J. Chem. Soc., Perkin Trans. 1*, (1980) 2866–2869.
- [25] J.E. Hook and B.Lindberg, *Acta. Chem. Scand.*, 22 (1968) 2157–2160.
- [26] B.H. Thewlis, *Stärke*, 278 (1975) 336–338.
- [27] J. Reuben, *Carbohydr. Res.*, 197 (1990) 257–261.

Note added in proof: the synthesis of 2-iodo-FDG has just been described; see J.D. McCarter, M.J. Adam, S.G. Withers, *Carbohydr. Res.* 266 (1995) 273–277.